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Abstract
Inhalation of fine particulate matter (<2.5 μm; fine PM) has been shown to increase the risk for cardiovascular
events. In this letter, we reappraise the role of tissue factor (TF) antigen and we also summarize changes in
measured coagulation proteins in humans and rodents by other studies with fine PM. By considering all studies
including ours, we conclude that monitoring the overall coagulation state by measuring capacity assays such as
thrombin generation, and quantification of TF activity would be more suitable than determining single coagulation
proteins (such as TF antigen) in order to better assess the systemic prothrombotic effects of fine PM.
Blood coagulation markers and fine PM exposure
studies
Evren Kilinç, Gerhardus JAJM Kuiper, Henri MH
Spronk, Hugo ten Cate
Earlier epidemiologic and experimental studies have
shown that fine particulate matter (<2.5 μm; fine PM)
inhalation is associated with arterial and venous thrombo-
sis, as well as an increased risk for cardiovascular death
[1]. Several studies have addressed the possible mechan-
isms involved in PM-related arterial and venous thrombo-
sis, although the recently published work by Emmerechts
et al. could not establish a direct effect of intratracheal PM
instillation on induction of venous thrombosis in mice [2].
Tissue factor (TF) is expressed in subendothelial cells
upon injury, or on the surface of cells like monocytes,
macrophages and neutrophils. A small amount of TF is
necessary to form a complex with factor VIIa to produce
thrombin via the extrinsic pathway of coagulation [3].
Since PM is also related to endothelial damage and
activation of platelets and macrophages upon short term
in vivo exposure [1], the measurement of TF in blood may
be considered as a marker of cell damage.
A recent publication in this journal, addressed the
effects of ambient fine PM in spontaneously hypertensive
rats (SHRs) following intratracheal instillation at varying
concentrations. Surprisingly, an early decrease in lung
specific tissue factor (TF) antigen was observed at 1 and
3 days post exposure, whereas plasminogen activator
inhibitor-1 (PAI-1) was increased at 1 day post instilla-
tion of fine PM [4].
It is known that a small proportion of TF exerts pro-
thrombotic effects and the inactive form of TF may not
reflect TF activity [3]. Additionally, tissue factor pathway
inhibitor (TFPI), the physiological inhibitor of TF, regu-
lates TF activity. Therefore, the measurements of TF anti-
gen in tissues do not necessarily reflect the functional
capacity and integrity of TF. Overall, measuring TF activity
could be a better approach for determining procoagulant
activity in tissues (local effect) and plasma (systemic effect).
Indeed, we recently showed that short-term inhalation
of fine PM increased lung specific TF activity at 4 and
48 hours post instillation as well as the overall procoagu-
lant potential of lung tissue, as assessed by thrombin gen-
eration, most likely through attenuated expression and
activity of the natural anticoagulant thrombomodulin [5].
In addition to rodent studies [6], different single coa-
gulation proteins have also been measured in humans
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exposed to fine PM [7-11]. The outcome of such studies
is rather inconsistent however, either with changes, or
no change in the levels of coagulation proteins, such as
factor VII (FVII), FVIII, FIX, FX. The specific responses
being most likely related to differences in fine PM
source and the dose used, as well as the time course of
sample collection and the experimental setup. At the
same time, it is likely that possible procoagulant reac-
tions to acute PM exposure will be downplayed by an
increased anticoagulant response as a systemic protec-
tive mechanism. Therefore, the balance in pro- and
anticoagulant reactions to PM will modulate the net
thrombotic events via thrombin, which is the critical
enzyme regulating the final common pathway leading to
fibrin formation [5].
In further studies of prothrombotic mechanisms of
PM, either after acute or chronic exposure, we would
advocate the use of overall capacity assays such as for
thrombin generation, in conjunction with TF activity
and specific anticoagulant proteins in order to better
understand the net contribution of fine PM to thrombo-
tic and cardiovascular events.
Response to Kilinç et al
Holger Schulz, Swapna Upadhyay, Koustav Ganguly,
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naka, Wolfgang G Kreyling, Mike Pitz, Peter Reitmeir,
Annette Peters, Oliver Eickelberg, and H Erich Wichmann
We appreciate the comments from Kilinç and coworkers
concerning application and interpretation of blood coagu-
lation markers in PM exposure studies. They suggest the
application of capacity assays rather than measurements of
single coagulation factors to better understand alterations
of the coagulation homeostasis in PM exposure studies.
With respect to our study [4], the functional activity of TF
in target organs would have been more suitable than mea-
surement of the antigen level in tissues. We agree with
Kilinç et al. that TF activity or even further coagulation
assays would certainly improve our understanding of the
complex response observed in our PM2.5 Augsburg
(PM2.5-AB) exposure study. Reliable activity assays evalu-
ated in correspondence to their protein/transcription
levels always provide essential functional information of
biological responses. However, our study was designed to
get a global impression of PM2.5-AB associated inflamma-
tory and cardiovascular effects in target organs and their
potential interactions rather than being specifically focused
on disturbances of the coagulation cascade. Related to
thrombogenic effects reported after PM exposures
[6,10,12-16], we selected TF and PAI-1 as representative
markers to assess deteriorations of the coagulation home-
ostasis. Increased levels of TF and PAI-1 were observed in
the heart three days after exposure to high PM2.5-AB.
This is in line with the common understanding that
inflammatory activity - as evidenced in our study by
increased levels of osteopontin and macrophage inflamma-
tory protein (MIP)2 in the heart and C- reactive protein
(CRP) in the serum - triggers TF mediated coagulation
[17]. The scenario observed in the lung appears to be
more complex, an early inflammatory response at day 1 is
associated with a reduced TF and an increased PAI-1 level
while at day 3 both markers, in particular PAI-1, were sub-
stantially down regulated. Most inflammatory markers
reached baseline levels at this time point [4]. Our data
indicate that PM2.5-AB exposure alters the coagulation
homeostasis in lungs and heart and shows that main target
organs exhibit a different response with respect to time
course and direction. As already mentioned by Kilinç et al.
these results are principally in line with reports from other
studies whereby differences in the PM source, the route of
administration, and the dose may explain the different
outcomes described so far with respect to the endpoints
selected. Indeed, uncovering the underlying pathomechan-
isms of PM2.5-AB associated effects on the homeostasis of
blood coagulation warrants further investigation and
would require the assessment of platelet function, major
pro- and anticoagulant pathways and may be even the
bidirectional interaction between inflammation and coagu-
lation [17]. It remains a task to specifically address this
issue by assessing protein levels and functional activity for
a set of key coagulation events including the assessment of
the tissue factor thrombomodulin balance and fibrin for-
mation as suggested by Kilinç et al.
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